The role of Doppler echocardiography in pulmonary artery hypertension: The importance of proving the obvious

Chest

Volumn 139, Issue 5, 2011, Pages 973-975

  Paterson, Ian ^a   Michelakis, Evangelos D ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL;

DOPPLER ECHOCARDIOGRAPHY; DRUG WITHDRAWAL; EDITORIAL; HEART CATHETERIZATION; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; LUNG WEDGE PRESSURE; MEAN ARTERIAL PRESSURE; PREDICTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SICKLE CELL ANEMIA; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

EID: 79955760241     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-2837     Document Type: Editorial

References (11)

1. Rich JD, Shah SJ, Swamy RS, Kamp A, Rich S. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest. 2011;139(5):988-993.
2. McLaughlin VV, Archer SL, Badesch DB, et al; ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc, and the Pulmonary Hypertension Association. Circulation. 2009;119(16):2250-2294.
3. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886-895. (Pubitemid 38252536)
4. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307-310. (Pubitemid 16134762)
5. Bachir D, Parent F, Hajji L, et al. Prospective multicentre survey on pulmonary hypertension (PH) in adults with sickle cell disease [Abstract # 572]. Blood. 2009;114(22):238.
6. Bunn HF, Nathan DG, Dover GJ, et al. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood. 2010;116(5):687-692.
7. Barst RJ, Mubarak KK, Machado RF, et al; ASSET study group. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol. 2010;149(3):426-435.
8. Halpern SD, Taichman DB. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest. 2009;136(1):37-43.
9. Tonelli AR, Mubarak KK, Li N, Carrie R, Alnuaimat H. Effect of balloon inflation volume on pulmonary artery occlusion pressure in patients with and without pulmonary hypertension. Chest. 2011;139(1):115-121.
10. Kitabatake A, Inoue M, Asao M, et al. Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation. 1983;68(2):302-309. (Pubitemid 13028906)
11. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006;174(9):1034-1041. (Pubitemid 44684453)